Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663190 | 0.84 | HSD11B1 (0.48) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL3910795 | 0.83 | HSD11B1 (0.53) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL5946875 | 0.81 | HSD11B1 (0.54) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL5662264 | 0.81 | POLB (0.42) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL3910792 | 0.78 | HSD11B1 (0.51) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL5662903 | 0.78 | CNR2 (0.52) | HSD11B1CNR2HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL5946691 | 0.77 | HSD11B1 (0.59) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL5946765 | 0.77 | HSD11B1 (0.59) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL5946802 | 0.77 | TP53 (0.47) | HSD11B1POLBTDP1CNR2HSD17B1 | |
| SCHEMBL5472445 | 0.76 | HSD11B1 (0.48) | HSD11B1POLBTDP1CNR2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | COPPOLA GARY M | 2006-09-14 | — | — | US | disclosed |
| EP-1590319-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004065351-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | HSD11B1 4758/4885POLB 2618/4885TDP1 2237/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | HSD11B1 4783/4885POLB 2324/4885TDP1 2562/4885 |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | HSD11B1, HSD11B2, CYP11B1 | HSD11B1 1/4885POLB 3116/4885TDP1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.